Although the addition of trifluridine/tipiracil (TAS-102; Lonsurf) to bevacizumab (Avastin) in the first line did not produce superior survival benefit vs standard capecitabine (Xeloda) and bevacizumab, similar efficacy results between both arms indicate that the regimen may still be a viable treatment for patients with unresectable metastatic colorectal cancer (mCRC) who are ineligible for intensive chemotherapy, according to Thierry André, MD.
Natco's Generic Tipiracil Hydrochloride, nTrifluridine Receives Approval in the U.S.
AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech’s candidate cancer treatment is being funded by the French National Cancer Institute (INCA). The study is headed by renown oncologists Dr. François Ghiringhelli and Dr. Come Lepage, Professor in Medical Oncology and Director of the INSERM research team at the Georges-Francois Leclerc Cancer Centre, and Professor at the Department of Gastroenterology and Digestive Oncology, University Hospital Dijon, Dijon, France, respectively.
AUSTIN, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the French National Agency for the Safety of Medicines and Health Products [L'Agence nationale de...
Natco Pharma Limited hasnlaunched a novel fixed-dose combination of Trifluridine + Tipiracil fornthe first-time in India under the brand name Tipanat as a pack of 20 ntablets in a bottle. Tipanat is a novel antineoplastic nucleoside analognindicated for the treatment of advanced colorectal and gastric cancer.
Natco Pharma Limited has launched a novel fixed-dose combination of trifluridine + tipiracil for the first-time in India under the brand name Tipanat as a pack of 20 tablets in a bottle.
FDA Confirms Paragraph IV Patent Challenge of Lonsurf 207981 (Trifluridine and Tipiracil) Tablets 15 mg/6.14 mg and 20 mg/8.19 mg
Servier and its partner Taiho Pharmaceutical Co., Ltd announced today that the European Commission (EC) has approved the use of LONSURF® (trifluridine/tipiracil) as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy
Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data